SKBA Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-108,400
Closed -$6.85M 78
2020
Q3
$6.85M Sell
108,400
-7,150
-6% -$496K 1.37% 40
2020
Q2
$8.89M Sell
115,550
-1,350
-1% -$103K 1.73% 27
2020
Q1
$8.74M Sell
116,900
-58,200
-33% -$4.02M 1.99% 24
2019
Q4
$11.4M Sell
175,100
-16,400
-9% -$1.07M 1.8% 28
2019
Q3
$12.1M Buy
191,500
+21,900
+13% +$1.43M 1.93% 22
2019
Q2
$11.5M Sell
169,600
-3,200
-2% -$211K 1.83% 23
2019
Q1
$11.2M Sell
172,800
-11,250
-6% -$748K 1.81% 29
2018
Q4
$11.5M Sell
184,050
-13,600
-7% -$951K 1.87% 27
2018
Q3
$15.3M Hold
197,650
1.98% 22
2018
Q2
$14M Sell
197,650
-1,600
-0.8% -$113K 1.89% 21
2018
Q1
$15M Buy
199,250
+500
+0.3% +$39.7K 2.04% 19
2017
Q4
$14.2M Buy
198,750
+36,600
+23% +$2.78M 1.98% 22
2017
Q3
$13.1M Buy
162,150
+19,650
+14% +$1.5M 1.89% 29
2017
Q2
$10.1M Buy
142,500
+35,900
+34% +$2.39M 1.53% 34
2017
Q1
$7.24M Buy
+106,600
New +$7.5M 0.96% 48
2016
Q4
Sell
-2,820
Closed -$223K 78
2016
Q3
$223K Buy
2,820
+200
+8% +$16.2K 0.02% 75
2016
Q2
$219K Hold
2,620
0.02% 76
2016
Q1
$241K Sell
2,620
-1,500
-36% -$135K 0.02% 78
2015
Q4
$417K Sell
4,120
-38,200
-90% -$3.97M 0.04% 73
2015
Q3
$4.16M Hold
42,320
0.36% 68
2015
Q2
$4.96M Hold
42,320
0.39% 65
2015
Q1
$4.15M Buy
+42,320
New +$4.3M 0.32% 68

Other funds holding GILD

SKBA Capital Management's GILD Position: Q4 2020 in Review

SKBA Capital Management sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 108,400 shares — an estimated $6.85M sold.

SKBA Capital Management first reported a position in GILD in Q1 2015 and held it in 22 quarters. The position peaked at $15.3M in Q3 2018. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

  • SKBA Capital Management reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
  • SKBA Capital Management sold 108,400 Gilead Sciences shares in Q4 2020, an estimated $6.85M.
  • SKBA Capital Management first reported a position in Gilead Sciences in Q1 2015 and held it in 22 quarters.
  • SKBA Capital Management's Gilead Sciences position peaked at $15.3M in Q3 2018.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on SKBA Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.